These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32107082)

  • 1. PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
    Fadia M; Fookeerah P; Ali S; Shadbolt B; Greenaway T; Perampalam S
    Pathology; 2020 Apr; 52(3):318-322. PubMed ID: 32107082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
    Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
    Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma.
    Banerjee S; Nahar U; Dahiya D; Mukherjee S; Dey P; Gupta R; Radotra B; Sachdeva N; Sood A; Bhadada SK; Bhansali A
    Front Endocrinol (Lausanne); 2022; 13():931647. PubMed ID: 36518249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
    Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
    Bai Y; Guo T; Huang X; Wu Q; Niu D; Ji X; Feng Q; Li Z; Kakudo K
    Virchows Arch; 2018 May; 472(5):779-787. PubMed ID: 29651624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 and B7-H3 are Effective Prognostic Factors and Potential Therapeutic Targets for High-Risk Thyroid Cancer.
    Zhu X; Hu C; Zhang Z; Zhu Y; Liu W; Zheng B; Feng X; Lu H
    Endocr Pathol; 2024 Sep; 35(3):230-244. PubMed ID: 39102163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
    Shi RL; Qu N; Luo TX; Xiang J; Liao T; Sun GH; Wang Y; Wang YL; Huang CP; Ji QH
    Thyroid; 2017 Apr; 27(4):537-545. PubMed ID: 27825291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
    Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
    Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 and PD-1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor.
    Pakkanen E; Kalfert D; Ahtiainen M; Ludvíková M; Kuopio T; Kholová I
    APMIS; 2022 May; 130(5):276-283. PubMed ID: 35238073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-10 Restores MHC Class I Expression and Interferes With Immunity in Papillary Thyroid Cancer With Hashimoto Thyroiditis.
    Lu ZW; Hu JQ; Liu WL; Wen D; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
    Endocrinology; 2020 Oct; 161(10):. PubMed ID: 32348468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
    Girolami I; Pantanowitz L; Mete O; Brunelli M; Marletta S; Colato C; Trimboli P; Crescenzi A; Bongiovanni M; Barbareschi M; Eccher A
    Endocr Pathol; 2020 Sep; 31(3):291-300. PubMed ID: 32468210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.
    Zhu C; Dai Y; Zhang H; Ruan Y; Zhou Y; Dai Y; Fan L; Jia T; Lu H; Chen Q
    Diagn Pathol; 2021 Aug; 16(1):84. PubMed ID: 34465342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
    Bai Y; Niu D; Huang X; Jia L; Kang Q; Dou F; Ji X; Xue W; Liu Y; Li Z; Feng Q; Lin D; Kakudo K
    Diagn Pathol; 2017 Oct; 12(1):72. PubMed ID: 28974264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin.
    Latrofa F; Ricci D; Montanelli L; Rocchi R; Piaggi P; Sisti E; Grasso L; Basolo F; Ugolini C; Pinchera A; Vitti P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2380-7. PubMed ID: 22539585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of lymphocytic thyroiditis on the prognostic outcome of patients with papillary thyroid carcinoma.
    Loh KC; Greenspan FS; Dong F; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1999 Feb; 84(2):458-63. PubMed ID: 10022401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
    Wang H; Zhang Z; Yan Z; Ma S
    Adv Clin Exp Med; 2020 Jul; 29(7):785-792. PubMed ID: 32750756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical analysis of lymphocytic thyroiditis coexistent with papillary thyroid carcinoma].
    Wang SX; She ZQ; An CM; Zhang XW; Li ZJ; Tang PZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Apr; 51(4):277-81. PubMed ID: 27095720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-17A increases MHC class I expression and promotes T cell activation in papillary thyroid cancer patients with coexistent Hashimoto's thyroiditis.
    Han LT; Hu JQ; Ma B; Wen D; Zhang TT; Lu ZW; Wei WJ; Wang YL; Wang Y; Liao T; Ji QH
    Diagn Pathol; 2019 Jun; 14(1):52. PubMed ID: 31159823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
    Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.